Knee Brace Offloads Osteoarthritis Superior Relief For Knee Articles & Analysis
18 news found
A new study published in BMC Musculoskeletal Disorders confirmed that biomechanical markers are more associated with pain, symptoms and disability compared to imaging findings in knee osteoarthritis patients. Researchers recommend the use of a complementary objective biomechanical evaluation using the KneeKG to conventional imaging to obtain a more complete functional profile of knee OA ...
ByEmovi
In partnership with The Geneva Foundation and supporting grant from the Quebec Ministry of Economy and Innovation, Emovi will launch the 24-month clinical project within US Army clinics at Fort Bragg and High Point University, North Carolina, USA Emovi, Inc., a leading medical device developer and manufacturer for orthopaedics, announced today a clinical collaboration with the US Army in ...
ByEmovi
Emovi, Inc., a global medical device developer, today announced a partnership with Sports Illustrated as a sponsor of the 2020 Sports Illustrated Awards (SI Awards) The SI Awards will take place in Las Vegas on December 19. Viewers can stream the primetime broadcast live via the Sports Illustrated Facebook page beginning at 7:00 PM ET . The award ceremony will feature special presentations, ...
ByEmovi
Active Implants LLC, a company that develops orthopedic implant solutions, today announced that two patients in Israel have undergone knee surgery for the company’s NUsurface® Meniscus Implant – the first “artificial meniscus” to be marketed in the Middle East. Until now, the NUsurface Implant was only available in Israel in clinical trials. The procedures were ...
Active Implants, LLC, a developer of orthopedic implant solutions for joint preservation, today announced two-year results of the MERCURY study, which showed that the company’s NUsurface® Meniscus Implant provides statistically superior pain relief beginning at six months compared to non-surgical therapy. The results were presented at the American Orthopedic Society for Sports ...
Belgian biotech company KiOmed Pharma and digital therapeutics company moveUP are pleased to announce the signature of an exclusive agreement for the development and licensing of a unique mobile health companion application dedicated to personalised conservative intra-articular treatment for patients suffering from osteoarthritis. This application is to be developed by moveUP, while exclusive ...
Emovi inc. is pleased to announce that Geisinger Health, comprised of nine hospital campuses, two research centers, a college of medicine, and a 550,000-member health plan serving more than three million residents in central, south-central, and northeast Pennsylvania, broadens its care and support for patients experiencing knee pain with the addition of five KneeKG Systems into their clinics. ...
ByEmovi
KiOmed Pharma, an innovative Belgian biotech company, has reported positive safety and efficacy outcomes following the treatment of nearly 80 patients suffering from Knee OsteoArthritis (OA). This European Healthcare Professional (HCP) survey yielded a global long-term improvement of OA symptoms and shows preliminary evidence of improved outcomes in patients with advanced stage OA. ‘This ...
Global Phase IIb study to enrol approximately 312 patients, each of whom will receive one of three doses of MM-II or placebo Primary endpoint is a reduction in pain from baseline as measured by WOMAC A pain scale at 12 weeks Israel-based Moebius Medical today announced that the first patient has been dosed in its Phase IIb clinical trial of MM-II, a novel candidate for the treatment of pain ...
The new program is designed for Canadian athletes to improve explosiveness, endurance, control, and stability as they prepare to compete on the world stage Emovi, Inc. announces the launch of its new program for Canadian athletes in collaboration with Gold Medal Olympian Bruny Surin. The Athlete Support Program invites athletes to integrate Emovi’s flagship device, the KneeKGTM, into their ...
ByEmovi
Treatment leverages proprietary liposomes and first-in-class mechanism-of-action to achieve significant, sustainable pain relief Phase IIb study expected to begin enrolling by year-end with initial top-line data anticipated in mid-2022 Israel-based Moebius Medical today announced that the US Food and Drug administration (FDA) has cleared their Investigational New Drug (IND) application to ...
Kinestique Diagnostic Centre announces today the launch of the KneeKGTM in their inaugural clinic, the firsts in the country and Southeast Asia. Developed by Emovi, the KneeKGTM is to the knee, what an EKG is for the heart, and provides valuable data that enables physicians and other healthcare professionals to determine the most appropriate patient-specific care plan to restore optimal knee ...
ByEmovi
Outpatient orthopedic and sports medicine rehabilitation provider, Intecore Physical Therapy, broadens its care and support for patients experiencing knee pain with the addition of the KneeKG™ System into all of their clinics. Developed by Emovi, the KneeKG™ is used on the knee, like an EKG is for the heart, by providing valuable data that enables the Physical Therapy team to ...
ByEmovi
FYZICAL Therapy and Balance Centers – El Paso, announces today the launch of KneeKGTM into all four of their locations. Developed by Emovi, the KneeKG is for the knee, like an EKG is for the heart and provides valuable data that enables physicians and other healthcare professionals to determine the most appropriate patient-specific care plan to restore optimal knee function. Knee pain is ...
ByEmovi
Stemmatters and Gelmetix have established an agreement to develop an innovative hydrogel based device for the treatment of cartilage lesions. The partnership established focuses on the pre-clinical development of the new device towards clinical studies in human patients and subsequent market authorization. The new medical device aims to ensure a significant advance in the treatment of ...
We are proud to announce that our rebranding process is now complete. Gelexir Healthcare, known for being a spin off of the University of Manchester and for its cutting edge R&D work on non-invasive treatments for Chronic Low Pain, officially becomes Gelmetix. This rebranding process has been developed in line with our new multi-product strategy, focused on three large unmet medical needs: ...
Hayward, CA, USA, March 15, 2017 – Moximed®, Inc., developer of unicompartmental load absorber implants for active patients with painful knee osteoarthritis (OA), announced today an oversubscribed Series C round of $50MM with new investors Advent Life Sciences and Future Fund joining existing investors NEA, Morgenthaler Ventures, Gilde Healthcare, GBS Venture Partners, and Vertex ...
Clinical data showed superior efficacy & similar safety of MM-II vs. standard of care (hyaluronic acid) for treatment of pain in osteoarthritis Sun Pharma to fund further development of MM-II including completion of Phase 2 and Phase 3 clinical programs and any required preclinical work necessary for regulatory approval Sun Pharma has worldwide commercialization & manufacturing rights ...